Moderna, Inc. (MRNA)
NASDAQ: MRNA · Real-Time Price · USD
27.70
+2.21 (8.67%)
At close: Dec 5, 2025, 4:00 PM EST
27.60
-0.10 (-0.36%)
After-hours: Dec 5, 2025, 7:59 PM EST
Moderna Revenue
Moderna had revenue of $1.02B in the quarter ending September 30, 2025, a decrease of -45.44%. This brings the company's revenue in the last twelve months to $2.23B, down -56.07% year-over-year. In the year 2024, Moderna had annual revenue of $3.24B, down -52.75%.
Revenue (ttm)
$2.23B
Revenue Growth
-56.07%
P/S Ratio
4.81
Revenue / Employee
$384,828
Employees
5,800
Market Cap
10.82B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.24B | -3.61B | -52.75% |
| Dec 31, 2023 | 6.85B | -12.42B | -64.45% |
| Dec 31, 2022 | 19.26B | 792.00M | 4.29% |
| Dec 31, 2021 | 18.47B | 17.67B | 2,200.25% |
| Dec 31, 2020 | 803.00M | 743.00M | 1,238.33% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MRNA News
- 3 days ago - Moderna, Inc. (MRNA) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - S&P 500 Gains and Losses Today: Moderna Falls; Synopsys Stock Climbs on Nvidia Partnership - Investopedia
- 4 days ago - FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks - Investopedia
- 4 days ago - Top Stock Movers Now: Coinbase, Robinhood, Moderna, Synopsys, and More - Investopedia
- 4 days ago - Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men - Market Watch
- 4 days ago - Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals - Barrons
- 11 days ago - Moderna, Inc. (MRNA) Analyst/Investor Day Transcript - Seeking Alpha
- 16 days ago - Moderna takes $1.5 billion loan, expects 10% revenue growth next year - Reuters